Tyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by Zacks Investment Research

Tyra Biosciences (NASDAQ:TYRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports.

According to Zacks, “Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company’s lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif. “

Several other analysts also recently commented on the stock. Cowen assumed coverage on shares of Tyra Biosciences in a report on Monday, October 11th. They issued an “outperform” rating on the stock. Jefferies Financial Group reissued a “hold” rating and set a $31.00 price target (up from $19.00) on shares of Tyra Biosciences in a report on Monday, November 8th. Finally, Bank of America started coverage on shares of Tyra Biosciences in a research report on Monday, October 11th. They set a “buy” rating and a $22.00 price objective for the company.

TYRA stock opened at $12.46 on Thursday. Tyra Biosciences has a 12 month low of $11.06 and a 12 month high of $31.36. The business’s 50-day moving average price is $18.23.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Tuesday, November 2nd. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.33). As a group, analysts predict that Tyra Biosciences will post -1.36 earnings per share for the current year.

In other news, major shareholder Boxer Capital, Llc bought 125,000 shares of Tyra Biosciences stock in a transaction that occurred on Friday, December 17th. The shares were purchased at an average price of $13.12 per share, with a total value of $1,640,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of large investors have recently bought and sold shares of TYRA. Perceptive Advisors LLC purchased a new stake in shares of Tyra Biosciences during the 3rd quarter worth $17,370,000. Janus Henderson Group PLC purchased a new stake in shares of Tyra Biosciences in the 3rd quarter worth about $22,844,000. Wellington Management Group LLP acquired a new position in Tyra Biosciences in the 3rd quarter valued at about $12,231,000. Millennium Management LLC acquired a new position in Tyra Biosciences in the 3rd quarter valued at about $1,645,000. Finally, BVF Inc. IL acquired a new position in Tyra Biosciences in the 3rd quarter valued at about $29,814,000. Hedge funds and other institutional investors own 81.48% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences Inc is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company’s lead product candidate includes TYRA-300. Tyra Biosciences Inc is based in CARLSBAD, Calif.

Featured Article: What is a Derivative?

Get a free copy of the Zacks research report on Tyra Biosciences (TYRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.